Practice

FDA recalls Philips Azurion systems over foot switch issue

The recall covers Azurion interventional fluoroscopy systems after Philips identified cases where X-ray imaging may not start or may occur intermittently when using the wired foot switch.

The U.S. Food and Drug Administration has issued a Class 2 recall for Philips Azurion interventional fluoroscopy systems after the company identified a wired foot switch issue.

X-ray imaging may not be initiated or may occur intermittently when the wired foot switch is used, according to the FDA recall record. The agency listed the determined cause as device design.

Philips sent urgent medical device correction letters to affected customers on March 3. Customers were instructed to circulate the letter to all users, perform a daily check before the first procedure of the day, report foot switch activation issues to a local Philips representative, and keep the letter with system documentation until correction is completed.

A related field safety notice dated February 26 described the issue as a potential loss of imaging functionality resulting from no or intermittent X-ray radiation initiation through the wired foot switch.

The correction applies to Philips Azurion systems manufactured by Philips Medical Systems Nederland in Best, Netherlands. The FDA recall entry lists the recall status as open.

PhilipsAzurionFDA Recall Class 2 RecallInterventional FluoroscopyX-ray ImagingWired Foot SwitchInterventional Radiology
Share

About the author

RadiologySignal.com writers

Editorial Team

Radiology Signal Staff covers developments across medical imaging, radiology AI, imaging informatics, clinical research, and radiology business. The team monitors primary sources, peer-reviewed studies, company announcements, society updates, and healthcare industry news to deliver concise reporting for imaging professionals.

More from this section